x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012083
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human GMPS protein. Antibodies are purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | GMPS |
| UniProt No. | P49915 |
| Gene ID | 8833 |
| Gene Description | Guanine monophosphate synthase catalyzes the conversion of xanthosine 5’-monophosphate into GMP during the final step of de novo guanine nucleotide synthesis. In addition to comprising the building blocks for DNA and RNA, guanine nucleotides also provide GTP for many signaling pathways that are important for multiple cellular processes. Chromosomal translocations involving MLL and GMPS is reported in some patients diagnosed with acute myeloid leukemia. Research studies indicate that genotoxic stress or nucleotide deprivation prompts translocation of GMPS to the nucleus where it complexes with USP7 and p53 to promote p53 stabilization. Additional studies show that the nuclear GMPS-USP7 protein complex deubiquitinates histone H2B in Drosophila. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
